%A Guo Chongyong, Li Yongmei, Li Bocheng, Zhou Ling, Zhang Jian, Jia Zongshi %T Expressions and clinical significances of aldehyde dehydrogenase 1 and transforming growth factor-β2 in triple negative breast cancer %0 Journal Article %D 2017 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2017.11.001 %P 801-805 %V 44 %N 11 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_10339.shtml} %8 2017-11-08 %X Objective To investigate the expressions and clinical significances of breast cancer stem cell markers such as aldehyde dehydrogenase 1 (ALDH1) and transforming growth factorβ2 (TGFβ2) in patients with triple negative breast cancer. MethodsSamples of 60 triple negative breast cancer tissues were investigated for the expressions of ALDH1 and TGFβ2 proteins by immunohistochemical staining. The correlation analysis, diseasefree survival analysis and overall survival analysis were performed. ResultsThe positive expressions of ALDH1 protein and TGFβ2 protein in the 60 breast cancer primary lesions were 23 cases (38.33%) and 38 cases (63.33%) respectively. The expression of ALDH1 protein was not correlated with tumor size (χ2=0.307, P=0.580), histological grade (χ2=4.244, P=0.120), clinical stage (χ2=0.982, P=0.612) or lymph node metastasis (χ2=1.111, P=0.292). The expression of TGFβ2 protein was not correlated with histological grade (χ2=4.651, P=0.098), lymph node metastasis (χ2=3.513, P=0.061), clinical stage (χ2=1.310, P=0.519) or tumor size (χ2=0.629, P=0.428). The diseasefree survival time ［(38.43±3.86) months vs. (53.38±2.58) months］ and the overall survival time ［(42.00±3.11) months vs. (53.84±2.19) months］ of ALDH1positive patients were significantly shorter than those of ALDH1negative patients, and the differences were statistically significant (χ2=8.490, P=0.004; χ2=11.270, P=0.001). The diseasefree survival time ［(42.81±3.32) months vs. (54.72±2.50) months］ and the overall survival time ［(44.74±2.68) months vs. (57.18±1.55) months］ of TGFβ2 positive patients were significantly shorter than those of TGFβ2negative patients, and the differences were statistically significant (χ2=4.300, P=0.038; χ2=8.900, P=0.003). The expression of ALDH1 protein was positively correlated with the expression of TGFβ2 protein (r=0.360, P=0.005). ConclusionThe ALDH1 phenotype is an independent predictor of poor prognosis. The activation of TGFβ2 signaling pathway may be involved in the regulation of triplenegative breast cancer stem cells.